Anticancer Drugs Olaparib Oncology Pharmacology Physiotherapy

Olaparib (Clinical Trials Experience-4)

In this article, we will discuss Olaparib (Clinical Trials Experience-4). So, let’s get started.

The safety of Olaparib capsules as maintenance monotherapy was also evaluated in patients with platinum sensitive ovarian cancer who had received 2 or more previous platinum containing regimens in Study, a randomized, placebo-controlled, double-blind, multi-center study in which 264 patients received Olaparib 400 mg twice daily (n=136) or placebo (n=128). At the time of final analysis, the
median duration of exposure was 8.7 months in patients who received Olaparib and 4.6 months in patients who received placebo.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.